Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aclidinium Bromide 200 µg · 2 trials · 2 indications
Change From Baseline in Morning Predose (Trough) FEV1 in liters at Week 52.
| Arm | Type | Description |
|---|---|---|
| Aclidinium Bromide 200 µg | EXPERIMENTAL | aclidinium bromide, inhaled, 52 weeks of treatment |
| Aclidinium Bromide 400 µg | EXPERIMENTAL | aclidinium bromide, inhaled, 52 weeks of treatment |
| Aclidinium bromide 200 μg bid | EXPERIMENTAL | Aclidinium bromide 200 μg twice-daily via inhalation |
| Aclidininum bromide 400 μg bid | EXPERIMENTAL | Aclidinium bromide 400 μg twice-daily via inhalation |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Aclidinium Bromide 200 µg | DRUG | aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment |
| Aclidinium Bromide 400 µg | DRUG | aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment |
| Aclidinium bromide 200 μg bid | DRUG | Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks |
| Aclidinium bromide 400 μg bid | DRUG | Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks |
| Placebo | DRUG | Placebo twice-daily by inhalation for 24 weeks |
Inclusion Criteria: * A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2010; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted * Current or former cigarette smokers Exc...
Aclidinium Bromide 200 µg is used for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is a small molecule being developed by AstraZeneca PLC (AZN) as an inhaled therapy for patients with this respiratory condition.
Aclidinium Bromide 200 µg is a small molecule designed to treat COPD by acting on the airways. Its mechanism involves bronchodilation, which helps open the airways to improve breathing in patients with chronic obstructive pulmonary disease.
Aclidinium Bromide 200 µg is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate the drug's efficacy and safety in COPD patients.
Aclidinium Bromide 200 µg is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trials are designed to assess its efficacy and safety in patients with COPD.
Aclidinium Bromide 200 µg has been studied in two completed Phase 3 trials. The first, NCT01001494, enrolled 828 patients with COPD across multiple countries. The second, NCT01044459, enrolled 605 patients with moderate to severe COPD in the United States and Canada.
Aclidinium Bromide 200 µg is a specific dose formulation of the drug aclidinium bromide. The 200 µg strength is being investigated for the treatment of COPD, and the clinical trials referenced evaluate this particular dose level.